Prelude Therapeutics, Inc. (PRLD)
1.65
-0.05
(-2.94%)
USD |
NASDAQ |
Dec 10, 16:00
1.65
0.00 (0.00%)
After-Hours: 20:00
Prelude Therapeutics EPS Diluted (Quarterly): -0.2591 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Incyte Corp. | 2.106 |
| Nautilus Biotechnology, Inc. | -0.1075 |
| Protalix Biotherapeutics, Inc. | 0.0291 |
| ALX Oncology Holdings, Inc. | -0.4133 |
| Erasca, Inc. | -0.1079 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.72M |
| Revenue (Quarterly) | 6.50M |
| Total Expenses (Quarterly) | 26.22M |
| Enterprise Value | 66.62M |
| Gross Profit Margin (Quarterly) | 93.46% |
| Profit Margin (Quarterly) | -303.5% |
| Earnings Yield | -97.78% |
| Normalized Earnings Yield | -97.78 |